Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.49 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.48 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.48 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | CASP1 | P29466 | 4/20 | 0.41 |
| ▸ | CASP7 | P55210 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tremuldin SCHEMBL1055081 | 0.86 | LGALS9 (0.55) | SLC28A3LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| Tremuldin SCHEMBL29402284 | 0.86 | LGALS9 (0.55) | SLC28A3LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL30527846 | 0.83 | SLC5A2 (0.51) | SLC28A3LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL30803061 | 0.80 | SLC28A3 (0.57) | SLC28A3SLC5A2SLC5A1HIF1A | |
| SCHEMBL4652290 | 0.79 | SLC28A3 (0.55) | SLC28A3LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL8360632 | 0.78 | LGALS3 (0.47) | SLC28A3LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| Salicin SCHEMBL8067421 | 0.78 | SLC5A2 (0.61) | SLC28A3SLC5A2SLC5A1HIF1AKDM4E | |
| Salicin SCHEMBL16238042 | 0.78 | SLC28A3 (0.53) | SLC28A3SLC5A2SLC5A1HIF1AKDM4E | |
| Itoside A SCHEMBL31677404 | 0.77 | LGALS9 (0.50) | LGALS9LGALS1LGALS3LGALS7; LGALS7BSLC5A2 | |
| SCHEMBL20009365 | 0.77 | LGALS3 (0.56) | SLC28A3LGALS9LGALS1LGALS3LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841342-B2 | Carrier | VITAL HEALTH SCIENCES PTY. LTD. (AU) | 2014-09-23 | — | — | US | claimed |
| US-8841342-B2 | Carrier | VITAL HEALTH SCIENCES PTY. LTD. (AU) | 2014-09-23 | — | — | US | disclosed |
| EP-1778289-B1 | CARRIER FOR ENTERAL ADMINISTRATION | VITAL HEALTH SCIENCES PTY LTD (AU) | 2011-01-12 | — | — | EP | disclosed |
| EP-2269650-A2 | Carrier for enteral administration | Vital Health Sciences Pty Ltd. (AU) | 2011-01-05 | — | — | EP | disclosed |
| EP-1460995-B1 | TRANSDERMAL TRANSPORT OF COMPOUNDS | VITAL HEALTH SCIENCES PTY LTD (AU) | 2010-11-10 | — | — | EP | disclosed |
| US-20100261670-A1 | COMPLEXES OF PHOSPHATE DERIVATIVES | WEST SIMON MICHAEL | 2010-10-14 | — | — | US | disclosed |
| US-20100222305-A1 | COMPLEXES OF PHOSPHATE DERIVATIVES | WEST SIMON MICHAEL | 2010-09-02 | — | — | US | disclosed |
| US-20090004166-A1 | Carrier For Enternal Administration | VITAL HEALTH SCIENCES PTY LTD (AU) | 2009-01-01 | — | — | US | disclosed |
| EP-1778289-A4 | CARRIER FOR ENTERAL ADMINISTRATION | VITAL HEALTH SCIENCES PTY LTD (AU) | 2008-02-13 | — | — | EP | disclosed |
| EP-1545621-A4 | CARRIER | VITAL HEALTH SCIENCES PTY LTD (AU) | 2007-11-21 | — | — | EP | disclosed |
| EP-1545621-A1 | CARRIER | Vital Health Sciences Pty Ltd. (AU) | 2005-06-29 | — | — | EP | disclosed |
| US-20050089495-A1 | Transdermal transport of compounds | VITAL HEALTH SCIENCES PTY LTD. (AU) | 2005-04-28 | — | — | US | disclosed |
| EP-1339413-A4 | COMPLEXES OF PHOSPHATE DERIVATIVES | VITAL HEALTH SCIENCES PTY LTD (AU) | 2004-12-15 | — | — | EP | disclosed |
| EP-1460995-A1 | TRANSDERMAL TRANSPORT OF COMPOUNDS | Vital Health Sciences Pty Ltd. (AU) | 2004-09-29 | — | — | EP | disclosed |
| US-20040097472-A1 | Complexes of phosphate derivatives | VITAL HEALTH SCIENCES PTY LTD. (AU) | 2004-05-20 | — | — | US | disclosed |
| US-20040052754-A1 | Complexes of phosphate derivatives | VITAL HEALTH SCIENCES PTY LTD. (AU) | 2004-03-18 | — | — | US | disclosed |
| WO-2004014432-A1 | CARRIER | VITAL HEALTH SCIENCES PTY LTD (AU) | 2004-02-19 | — | — | WO | disclosed |
| EP-1339413-A1 | COMPLEXES OF PHOSPHATE DERIVATIVES | Vital Health Sciences Pty Ltd. (AU) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003049774-A1 | TRANSDERMAL TRANSPORT OF COMPOUNDS | VITAL HEALTH SCIENCES PTY LTD (AU) | 2003-06-19 | — | — | WO | disclosed |
| WO-2002040034-A1 | COMPLEXES OF PHOSPHATE DERIVATIVES | VITAL HEALTH SCIENCES PTY LTD. (AU) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004166-A1 | Carrier For Enternal Administration | SLC10A2, FABP2, SLC46A1 | SLC28A3 39/4885LGALS9 3149/4885LGALS1 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.